Ulcerative Colitis | Pharmacor | G7 | 2015

Last Updated 15 September 2015
Ulcerative colitis (UC) affects approximately 1.25 million people across the major markets. Aminosalicylates and corticosteroids are routinely prescribed for mild and moderate patients; however, substantial opportunity exists for new treatment options that can more effectively induce or maintain remission in moderate to severe patients than existing therapies. Vedolizumab (Takeda’s Entyvio) is a recently approved cell adhesion molecule inhibitor that offers a novel mechanism of action. Tofacitinib (Pfizer’s Xeljanz), etrolizumab (Roche/Genentech), and ozanimod (Receptos) are emerging therapies in late-stage development for moderate to severe UC. This report provides a detailed analysis and an annualized ten-year forecast of the UC market extending into 2024. Detailed epidemiological estimates and in-depth coverage of both current and emerging therapies are also included.